News

3D bioprinted lungs to be available for global transplants

Share |

Israel’s Collplant inks licensing and commercialization deal with major American biotech firm to make human organs.

 

CollPlant, an Israeli regenerative medicine company focused on 3D bioprinting of tissues and organs, signed a license, development and commercialization agreement with United Therapeutics Corporation of Maryland for 3D bioprinted lung transplants.

The agreement combines CollPlant’s proprietary recombinant human collagen (rhCollagen) derived from engineered tobacco plants, and its BioInk technology, with the regenerative medicine and organ manufacturing capabilities of United Therapeutics subsidiary Lung Biotechnology PBC.

Read more at Israel21c.